Side effects in the modern psychopharmacology of depression

Primary Psychiatry

Volumn 14, Issue 7, 2007, Pages 50-58

  Rosse, Richard B ^a,b,e   Fanous, Ayman ^a,c,d   Gaskins, Brooke L ^a   Deutsch, Stephen I ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HOWARD UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; DULOXETINE; ELETRIPTAN; ESCITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE MALEATE; FROVATRIPTAN; LIOTHYRONINE; LITHIUM; MAXALT MLT; MIRTAZAPINE; NARATRIPTAN; NORTRIPTYLINE; PAROXETINE; RIZATRIPTAN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; SUMATRIPTAN SUCCINATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ZOLMITRIPTAN; ZOMIG ZMT;

AGITATION; ANORGASMIA; ANTICHOLINERGIC EFFECT; ANXIETY; APPETITE DISORDER; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG HALF LIFE; FATIGUE; HEADACHE; HEAT INTOLERANCE; HUMAN; HYPERTENSION; HYPOMANIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INCREASED APPETITE; INSOMNIA; LIBIDO DISORDER; MANIA; MUSCLE WEAKNESS; NAUSEA; NERVOUSNESS; ORGASM DISORDER; PSYCHOPHARMACOLOGY; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDE; SYNCOPE; THIRST; TREATMENT OUTCOME; TREMOR; UPPER GASTROINTESTINAL BLEEDING; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 34547328653     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Rush AJ, Trivedi M, Fava M. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry. 2003;160(2):237.
2. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243- 1252.
3. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-1530.
4. Haddad P, Lejoyeux M, Young A. Antidepressant discontinuation reactions. BMJ. 1998;316(7138):1105-1106.
5. Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord. 1999;52(1-3):135-144.
6. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disorder. 2005;85(3);245-258.
7. Akiskal HS, Benazzi F. The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum. J Affect Disord. 2006;92(1):45-54.
8. Benazzi F. Challenging the unipolar-bipolar division: does mixed depression bridge the gap? Prog Nemopsychopharmacol Biol Psychiatry. 2007;30;31(1):97-103.
9. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry. 1994;55(9):394-400.
10. Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol. 2001;16(7):495-505.
11. Class suicidality labeling language for antidepressants. Available at: www.fda.gov/cder/drug/antidepressants/Pl_template.pdf. Accessed May 29, 2007.
12. National suicide prevention life-line. 1-800-273-TALK. Available at: www.suicidepreventionlife-line.org. Accessed May 29, 2007.
13. Stop a Suicide Today. Available at: www.stopasuicide.org. Accessed May 29, 2007.
14. Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol. 2006;26(6):587-594. Erratum in: J Clin Psychopharmacol. 2007;27(1):57.
15. Szanto K, Mulsant BH, Houck PR, et al. Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old age. J Affect Disord. 2007;98(1-2):153-161.
16. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry. 2006;63(12):1358-1367.
17. Stahl SM, Mendels J, Schwartz GE. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. J Clin Psychopharmacol. 2002;22(4):388-392.
18. Barclay TS, Lee AJ. Citalopram-associated SIADH. Ann Pharmacother. 2002;36(10):1558-1563.
19. Romero S, Pintor L, Serra M, et al. Syndrome of inappropriate secretion of antidiuretic hormone due to citalopram and venlafaxine. Gen Hosp Psychiatry. 2007;29(1):81-84.
20. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40(9):1618-1622.
21. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713.
22. FDA Public Health Advisory. Combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. Available at: www.fda.gov/cder/drug/ advisory/SSRI_SS200607.htm. Accessed May 29, 2007.
23. Isbister G, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277-285.
24. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120.
25. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615-619.
26. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1)-.100-109.
27. Boddy R, Ali R, Dowsett R. Use of sublingual olanzapine in serotonin syndrome [abstract]. J Toxicol Clin Toxicol. 2004;42:725.
28. Li N, Wallen NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis. 1997;8(8):517-523.
29. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163(1):59-64.
30. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med. 2006;119(9):719-727.
31. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323(7314):655- 658.
32. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279(8):609-610.
33. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015.
34. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80(1):18-27.
35. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79(4):301-308.
36. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol. 2006;22(4):571-575.
37. Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ. 2005;173(11):1320-1321.
38. FDA Public Health Advisory. Paroxetine. Available at: www.fda.gov/cder/drug/advisory/paroxetine200512.htm. Accessed May 29, 2007.
39. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60(7):720-726.
40. Lee A, Woo J, Ito S. Frequency of infant adverse events that are associated with citalopram use during breast-feeding. Am J Obstet Gynecol. 2004;190(1):218-221.
41. Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry. 2001;179:163-166.
42. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(6):1066-1078.